B
BriaCell Therapeutics Corp. (BCTX)
NCM – Real Time Price. Currency in USD
3.06
+0.09 (3.03%)
At close: Jun 26, 2026, 4:00 PM EDT
3.10
+0.04 (1.31%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.06
+0.09 (3.03%)
At close: Jun 26, 2026, 4:00 PM EDT
3.10
+0.04 (1.31%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Cash reserves $6.9M barely cover the upcoming debt maturities $0.0
Total current assets $25.4M exceed Total current liabilities $3.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-257.2x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$7.2M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.07 | 6.05 | 10 | |
| Quick ratio | 7.07 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | -257.19 | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -15K | -16K | -83K | -107K | -113K |
| Operating Income | -15M | -24M | -33M | -27M | -32M |
| Net Income | -27M | -21M | -5M | -26M | -31M |
| EBITDA | -15M | -24M | -33M | -27M | -32M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | N/A | 1.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | N/A | 1.0 |
| Next year | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 1.74 | N/A | 11.14 | 5.3 |
| Y/Y | 999 | -14.44 | N/A | 2.09 | 3.8 |
| 3y average | 999 | -120.68 | N/A | -37.48 | 3.3 |
| 5y average | 999 | -146.57 | N/A | -150.1 | 3.3 |
| Weighted average score | 3.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |